Company data
Alnylam Pharmaceuticals, Inc. employees and revenue per employee
ALNY · Biotechnology · $29.4B market cap
Alnylam Pharmaceuticals, Inc. had 2,500 employees at the end of fiscal Dec 2025, up 12.1% from a year earlier. Revenue for the year was $3.71B, up 65.2% from a year earlier, or $1.49M per employee. Revenue and headcount both grew, and revenue grew faster.
Employees
2,500
+12.1% YoY
Revenue
$3.71B
+65.2% YoY
Revenue / employee
$1.49M
Peer median $602K
Rank in industry
9 of 39
Biotechnology
Open roles
115
46 per 1,000 staff
Headcount against revenue
Both lines start at 100 in the first year we hold, so you can see which one grew faster.
Hover a year for the numbers.
| Year ending | Employees | Revenue | Per employee | Staff YoY | Revenue YoY |
|---|---|---|---|---|---|
| Dec 2025 | 2,500 | $3.71B | $1.49M | +12.1% | +65.2% |
| Dec 2024 | 2,230 | $2.25B | $1.01M | +6.2% | +23.0% |
| Dec 2023 | 2,100 | $1.83B | $871K | +4.9% | +76.2% |
| Dec 2022 | 2,002 | $1.04B | $518K | +20.2% | +22.9% |
| Dec 2021 | 1,665 | $844M | $507K | +14.6% | +71.3% |
| Dec 2020 | 1,453 | $493M | $339K | +9.8% | +124.3% |
| Dec 2019 | 1,323 | $220M | $166K | +24.2% | +193.4% |
| Dec 2018 | 1,065 | $74.9M | $70K | +42.2% | -16.7% |
| Dec 2017 | 749 | $89.9M | $120K | +45.7% | +90.7% |
| Dec 2016 | 514 | $47.2M | $92K | — | — |
Open roles on its job board: 115 (46 per 1,000 staff, against its latest annual headcount), as of 2026-10-07. Tracked since 2026-10-03. No 90 day change yet.
Alnylam Pharmaceuticals, Inc. against similar companies
The closest industry peers by revenue, from Biotechnology.
| Company | Employees | Revenue | Revenue / employee | Shape |
|---|---|---|---|---|
| UTHR United Therapeutics Corporation | 1,400 | $3.18B | $2.27M | Efficient growth |
| EXEL Exelixis, Inc. | 1,077 | $2.32B | $2.15M | Leaner |
| INCY Incyte Corporation | 2,844 | $5.14B | $1.81M | Efficient growth |
| PTCT PTC Therapeutics, Inc. | 991 | $1.73B | $1.75M | Efficient growth |
| ALNY Alnylam Pharmaceuticals, Inc. | 2,500 | $3.71B | $1.49M | Efficient growth |
| NBIX Neurocrine Biosciences, Inc. | 2,000 | $2.86B | $1.43M | Efficient growth |
| BMRN BioMarin Pharmaceutical Inc. | 3,221 | $3.22B | $1.00M | Efficient growth |
| MRNA Moderna, Inc. | 4,700 | $1.94B | $414K | Contracting |
| FTRE Fortrea Holdings Inc. | 14,300 | $2.72B | $190K | Leaner |
Questions about Alnylam Pharmaceuticals, Inc.
- How many employees does Alnylam Pharmaceuticals, Inc. have?
- Alnylam Pharmaceuticals, Inc. reported 2,500 employees for the fiscal year ending Dec 2025, in the annual report it filed on February 12, 2026. That is up 12.1% from a year earlier.
- What is Alnylam Pharmaceuticals, Inc.'s revenue per employee?
- Alnylam Pharmaceuticals, Inc. brought in $3.71B of revenue in fiscal Dec 2025, which is $1.49M per employee. That ranks 9 of 39 companies we track in Biotechnology, where the median is $602K.
- Is Alnylam Pharmaceuticals, Inc. hiring?
- Alnylam Pharmaceuticals, Inc.'s public job board listed 115 open roles on October 7, 2026, about 46 per 1,000 staff.
- Where do these numbers come from?
- Employee counts and revenue are taken from each company's own annual report (Form 10-K). Open roles are counted from the company's public job board where we have matched one. Companies report headcount once a year, sometimes rounded, so small changes can be noise.
Free game
Think you can pick better than the S&P 500?
Pick 15 stocks, lock them in, and we score them against the index every trading day for ten years. Free, with a public leaderboard.
Enter the challengeMore data
Compare ALNY with the rest of the market
See who earns the most per employee, who is hiring, and who is cutting, across every company we track.
Source: employee counts and revenue as stated in Alnylam Pharmaceuticals, Inc.'s annual reports (Form 10-K), latest filed February 12, 2026. This is data, not a recommendation to buy or sell ALNY.